SASimon Akerman

Simon Akerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Akerman has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel targets in headache: A narrative review

    by Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman

    Objectives/Background: This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently discovered targets that are undergoing preclinical through advanced clinical development, for the prevention and treatment of headache disorders. Headache disorders affect over one billion individuals worldwide and represent a major public health burden. Although CGRP‐targeted therapies have transformed migraine care, a substantial proportion of patients do not achieve adequate relief or remain untreated. Therefore, there is the need to identify and validate novel mechanistic targets across the full spectrum of headache disorders. Methods: This narrative review reports preclinical and clinical evidence for emerging therapeutic targets in headache, with a focus on those presented at the 2025 Scottsdale meeting of the American Headache Society, during the Advanced Science session. Literature searches were performed on specific topic areas using PubMed/Scopus to find relevant peer‐reviewed literature, as well as studies in ongoing clinical trial registries. Results: In addition to their established efficacy in migraine, CGRP‐targeted therapies are increasingly being explored across other headache disorders, reflecting their broader relevance to headache pathophysiology. Beyond CGRP, several promising targets have emerged. PACAP has been identified as a CGRP‐independent headache mediator, supported by robust preclinical data and two phase 2 trials demonstrating preventive efficacy with a PACAP monoclonal antibody in migraine. The endocannabinoid system shows antinociceptive potential, particularly through multitarget modulation of cannabinoid receptors and endocannabinoid‐degrading enzymes. Several therapeutic targets in earlier stages of development are also gaining attention. Among these, prolactin signaling and orexin‐2 receptor pathways represent sex‐specific mechanisms, demonstrating female‐specific and male‐specific relevance in headache‐related nociception, respectively. Additionally, protease‐activated receptor‐2 is implicated in dural‐trigeminovascular nociceptive sensitization and advancing through early clinical development. Finally, modulation of reactive nitroxidative species with peroxynitrite has emerged as an early‐stage strategy given its role in trigeminovascular sensitization and central pain maintenance. Conclusion: Altogether, these emerging targets expand the therapeutic landscape for headache disorders beyond CGRP and support a shift toward alternative, sex‐informed, and potentially combinatorial approaches for headache prevention and treatment, with the potential to benefit the untreated portion of patients.

  • Open Access

    Orofacial pain disorder or trigeminal autonomic cephalalgia? Insights into pathophysiology and implications in medicine and dentistry

    by Marcela Romero‐Reyes, Simon Akerman

    Objective: This narrative review highlights the importance of orofacial pain considerations in the differential diagnosis of trigeminal autonomic cephalalgias (TACs)/trigeminal autonomic orofacial pains (TAOPs). In addition, we provide novel insights into the pathophysiology of the presentation of TACs in the maxillary (V2) and mandibular (V3) trigeminal distributions (TAOPs). Background: TACs are lifelong disorders characterized by severe unilateral head pain accompanied by cranial autonomic phenomena. However, the head pain experienced may refer to the face, be present solely in the orofacial region as TAOPs, or even be experienced as a toothache. These presentations, involving V2/V3, may resemble disorders of diverse etiology and pathophysiology that may share some similarities with TACs, confusing the patient while relating symptoms, and creating a diagnostic dilemma for the clinician potentially leading to misdiagnosis. Moreover, TACs pathophysiology has not been discussed in relation to V2/V3 presentations (TAOPs). Methods: A literature search was performed on PubMed/Scopus to find relevant literature about TACs and TAOPs, and case reports of orofacial presentations. Deep reanalysis of several of our published articles on preclinical models of TACs was conducted to assess potential of V2‐V3 components. Results: TACs orofacial presentations are not as common but if present can lead to misdiagnosis with significant consequences. Patients presenting TACs involving the midface as TAOPs experience an important delay for a correct diagnosis including multiple and diverse health provider visits, with a risk of having well‐intended but misguided procedures. Differential diagnosis considerations need to include dental/odontogenic causes, sinusitis, temporomandibular disorders, Eagle syndrome, trigeminal neuralgia, and migraine (orofacial migraine, neurovascular orofacial pain). A reanalysis of preclinical data provides novel insights into this orofacial involvement. In two TAC‐specific preclinical neuronal populations, recording either trigeminal or superior salivatory nucleus neurons, it was observed that ~20% and 37.5% of neurons, respectively, had cutaneous receptive fields that included or were exclusively within the V2‐V3 trigeminal division. Whereas the numbers are not large, these demonstrate that even in rodent models in neuronal populations that could be considered TAC‐like, they can extend to, or exclusively involve, the facial region, similar to TAOPs. Conclusion: The potential presence of TACs in the orofacial region can be observed from preclinical models to the clinical setting. The International Classification of Headache Disorders (ICHD) needs to recognize this additional localization, as well as the intraoral one, including dental structures. Education about TACs/TAOPs in the medical and dental setting is vital. Evidence has shown that dentists are one of the first providers that are seen by this patient population due to similarities with dental pain. The dentist specialized in orofacial pain is a key ally in the identification of TACs/TAOPs. The medical/neurology and dental/orofacial pain settings have a great opportunity and responsibility to work together to stop years of pain in this patient population. image

  • Open Access

    Targeting peroxynitrite production in a model of persistent temporomandibular disorder comorbid with migraine

    by Simon Akerman, Ana Belen Salinas‐Abarca, Wei Guo, Daniela Salvemini, Marcela Romero‐Reyes

    Background and Purpose: The persistence of temporomandibular disorders (TMDs), particularly myogenous, in a person with migraine can lead to exacerbated clinical outcomes and limited response to treatment. The pro‐nociceptive reactive nitroxidative species, peroxynitrite, is involved in migraine mechanisms, but little is known of its role in this comorbidity. Here, we validate a model of persistent TMD comorbid with migraine in rats and dissect the role of peroxynitrite in its underlying nociceptive mechanisms, and as a novel therapeutic target. Experimental Approach: A combination of masseteric muscle injection of CFA and delayed CGRP infusion were used to model persistent myogenic‐TMD comorbid with migraine, respectively. Using electrophysiological and behavioural methods, we assessed migraine‐like neuronal outcomes and periorbital withdrawal thresholds to validate this approach. We measured 3‐nitrotyrosine expression, as a marker of nitroxidative species, including peroxynitrite, and used the peroxynitrite decomposition catalyst, FeTPPS, and to determine the role of peroxynitrite in these comorbid mechanisms. Key Results: Persistent myogenic‐TMD exacerbated migraine‐relevant neuronal outcomes in response to delayed CGRP, causing more prevalent and hypersensitive trigeminovascular neuronal responses to innocuous/noxious probing of dural and cutaneous‐periorbital regions, demonstrating many of the signatures of ‘latent sensitization’. We also observed increased expression of 3‐nitrotyrosine along the trigeminal pain pathway in TMD, migraine and comorbid models and confirm that targeting peroxynitrite breakdown prevents the development of this nociceptive neuronal phenotype. Conclusion and Implications: Our persistent comorbid myogenic‐TMD/migraine model translates to the exacerbated clinical phenotype, validating it as an approach to study mechanisms. Production of peroxynitrite along the trigeminal pain pathway contributes to the mechanisms underlying this phenotype and is a potentially novel monotherapy or combination approach.

  • Open Access

    The therapeutic pipeline in migraine: What does the future hold?

    by Mohammed Gamal-Eltrabily, Ana Belen Salinas-Abarca, Marcela Romero-Reyes, Simon Akerman


  • The role of stress in the comorbidity of migraine and other chronic primary pain

    by Shi‐Jie Zhao, Ting‐Ting Wang, Qi Zhang, Simon Akerman, Dong‐Yuan Cao

    Background: Chronic migraine is one of the most common causes of headache, belonging to the chronic primary pain (CPP) classification, along with fibromyalgia syndrome (FMS), temporomandibular disorders (TMD), and irritable bowel syndrome (IBS), based on the International Classification of Diseases‐11. The comorbidity between these pain disorders is commonly seen in the clinic. Stress directly and indirectly affects the pathophysiological mechanisms related to migraine and plays an important role in the co‐occurrence and development of migraine, FMS, TMD, and IBS. Methods: We systematically searched PubMed and Web of Science databases, using combined keywords: stress, migraine, comorbidity, fibromyalgia syndrome, temporomandibular disorders, irritable bowel syndrome, pathological mechanisms, animal models, and treatment strategies, while emphasizing high impact studies. Literature was screened based on relevance, scientific rigor, and evidence level, prioritizing studies on stress‐related comorbidity mechanisms, models, or treatments. Exclusion criteria included single case reports, non‐full‐text conference abstracts, non‐English articles, low‐relevance studies, low‐quality methodologies, and general opinions (except authoritative consensus/guidelines). Results: Clinical and preclinical studies support that potential stress‐related mechanisms underlie these comorbidities, including dysfunction of hypothalamic–pituitary–adrenal axis, dysregulation of autonomic nervous system, and central sensitization. We highlight the development and application of preclinical stress‐induced comorbid models as crucial tools for investigating these shared mechanisms. Stress targeted interventions have potential in managing these conditions, but mechanisms and efficacy stability remain to be clarified. Conclusion: Stress may be a key driver of migraine and CPP comorbidities. Stress induced preclinical models support mechanism exploration, and stress‐targeted therapies hold promise for improving patient prognosis. Future research should deepen mechanistic studies and optimize models/therapies to enhance clinical care.


  • Open Access

    Optimising combined treatment for migraine and temporomandibular disorders (TMDs)

    by Marcela Romero-Reyes, Simon Akerman, Alan M. Rapoport

    Temporomandibular disorders (TMDs) and migraine are highly prevalent, overlapping pain conditions that cause considerable burden in the population. These two disorders are of different etiology and pathophysiology, but both are mediated by the trigeminal system. Due to the interrelated anatomy and physiology of the craniofacial and cervical structures, shared molecular links and mutual feedback, there is an inherent potential for exacerbation of symptomatology, perpetuation and progression; however, on a positive note, there is good potential for developing integrated, mutually beneficial management protocols when migraine and TMDs are comorbid. Currently, there are no established protocols of management, and the literature is limited in studies exploring dual therapeutic protocols. So, the question is, how can management be optimized with the evidence available? We should start by recognizing the need for multidisciplinary management to improve patient outcomes and we must highlight the importance of the dialogue between headache medicine and dentistry. The meeting point is where the dental discipline and the specialty of orofacial pain reside. The underlying pathophysiology of this comorbidity points to the need to decrease mutual exacerbation inputs. Therefore, it is fundamental to identify contributing factors of potential sensitization, such as the presence of parafunctional behaviors, cervical spine contributors, the presence of other comorbidities and headache hygiene. Current evidence supports management recommendations that should be developed by a multidisciplinary team as an integrated plan with combination therapy including both pharmacological and non-pharmacological approaches to optimize management. This multidisciplinary team should include the medical provider (neurologist/headache medicine expertise), the dentist specialized in orofacial pain, the physical therapist and the behavioral medicine specialist. Research is needed to support evidence-based integrated protocols for the management of comorbid migraine and TMDs. Evidence has shown that calcitonin gene-related peptide (CGRP) is also involved in TMDs. CGRP-targeting therapies may hold future opportunities for pharmacological monotherapy addressing this comorbidity.


  • Top Cited Papers
    Open Access

    The role and interaction of hypothalamic-related neurotransmitters in migraine

    by Ana Belen Salinas-Abarca, Mohammed Gamal-Eltrabily, Marcela Romero-Reyes, Simon Akerman

    Migraine is a complex neurological disorder frequently associated with hypothalamic dysfunction. This brain region is essential for maintaining homeostasis due to its regulation of autonomic, endocrine, and circadian systems. While the pathophysiology of migraine remains incompletely understood, clinical features such as the cyclic nature of attacks and symptoms, including nausea, vomiting, yawning, irritability, and sensitivity to light, indicate a significant role for the hypothalamus. Further, potential triggers of migraine, such as stress and disruption to feeding habits, also impact hypothalamic mechanisms. The higher prevalence of migraine in women compared to men suggests a link to hormonal fluctuations involving estrogen, progesterone, and prolactin. These hormones interact with the hypothalamus, potentially influencing the onset and severity of migraine episodes. Additionally, the hypothalamus synthesizes neuropeptides such as orexins, neuropeptide Y, PACAP, oxytocin, and vasopressin, which are all implicated in migraine mechanisms. Understanding the interplay between the hypothalamus, sex hormones, and neuropeptides offers valuable opportunities for endogenous targeted migraine therapies. In this review we discuss hypothalamic contributions to migraine pathophysiology, highlighting the mechanisms affected by hypothalamic connections, neuropeptides, and hormones, and their role as migraine triggers, particularly focusing on factors like stress, fasting, and changes in sleep patterns.


  • PACAP‐38 related modulation of the cranial parasympathetic projection: A novel mechanism and therapeutic target in severe primary headache

    by Simon Akerman, Peter J. Goadsby, Marcela Romero‐Reyes

    Background and Purpose: Little is known of how cranial autonomic symptoms (CAS) in cluster headache and migraine may contribute to their severe headache phenotype. This strong association suggests the involvement of the cranial parasympathetic efferent pathway. To investigate its contribution, we studied the role of pituitary adenylate cyclase activating polypeptide‐38 (PACAP‐38), a potent sensory and parasympathetic neuropeptide, in modulating pre‐ and post‐ganglionic cranial parasympathetic projection neurons, and their influence on headache‐related trigeminal‐autonomic responses.Experimental Approach: Using PACAP‐38 and PACAP‐38 responsive receptor antagonists, electrophysiological, behavioural and facial neurovascular‐blood flow was measured in rats to probe trigeminal‐ and parasympathetic‐neuronal, periorbital thresholds and cranial‐autonomic outcomes, as they relate to primary headaches.Key Results: Sumatriptan attenuated the development of PACAP‐38 mediated activation and sensitization of trigeminocervical neurons and related periorbital allodynia. PACAP‐38 also caused activation and enhanced responses of dural‐responsive pre‐ganglionic pontine‐superior salivatory parasympathetic neurons. Further, the PACAP‐38 responsive receptor antagonists dissected a role of VPAC1 and PAC1 receptors in attenuating cranial‐autonomic and trigeminal‐neuronal responses to activation of the cranial parasympathetic projection, which requires post‐ganglionic parasympathetic neurotransmission.Conclusion and Implications: Given the prevailing view that sumatriptan acts to some degree via a peripheral mechanism, our data support that PACAP‐38 mediated receptor activation modulates headache‐related cranial‐autonomic and trigeminovascular responses via peripheral and central components of the cranial parasympathetic projection. This provides a mechanistic rationale for the association of CAS with more severe headache phenotypes in cluster headache and migraine, and supports the cranial parasympathetic projection as a potential novel locus for treatment by selectively targeting PACAP‐38 or PACAP‐38 responsive VPAC1/PAC1 receptors.


  • Pharmacological Management of Orofacial Pain

    by Marcela Romero-Reyes, Sherwin Arman, Antonia Teruel, Satish Kumar, James Hawkins, Simon Akerman

    Orofacial pain is a category of complex disorders, including musculoskeletal, neuropathic and neurovascular disorders, that greatly affect the quality of life of the patient. These disorders are within the fields of dentistry and medicine and management can be challenging, requiring a referral to an orofacial pain specialist, essential for adequate evaluation, diagnosis, and care. Management is specific to the diagnosis and a treatment plan is developed with diverse pharmacological and non-pharmacological modalities. The pharmacological management of orofacial pain encompasses a vast array of medication classes and approaches. This includes anti-inflammatory drugs, muscle relaxants, anticonvulsants, antidepressants, and anesthetics. In addition, as adjunct therapy, different injections can be integrated into the management plan depending on the diagnosis and needs. These include trigger point injections, temporomandibular joint (TMJ) injections, and neurotoxin injections with botulinum toxin and nerve blocks. Multidisciplinary management is key for optimal care. New and safer therapeutic targets exclusively for the management of orofacial pain disorders are needed to offer better care for this patient population.


  • Open Access

    Pharmacological modulation of ventral tegmental area neurons elicits changes in trigeminovascular sensory processing and is accompanied by glycemic changes: Implications for migraine

    by Margarida Martins-Oliveira, Simon Akerman, Philip R Holland, Isaura Tavares, Peter J Goadsby

    Background: Imaging migraine premonitory studies show increased midbrain activation consistent with the ventral tegmental area, an area involved in pain modulation and hedonic feeding. We investigated ventral tegmental area pharmacological modulation effects on trigeminovascular processing and consequent glycemic levels, which could be involved in appetite changes in susceptible migraine patients.Methods: Serotonin and pituitary adenylate cyclase-activating polypeptide receptors immunohistochemistry was performed in ventral tegmental area parabrachial pigmented nucleus of male Sprague Dawley rats. In vivo trigeminocervical complex neuronal responses to dura mater nociceptive electrical stimulation, and facial mechanical stimulation of the ophthalmic dermatome were recorded. Changes in trigeminocervical complex responses following ventral tegmental area parabrachial pigmented nucleus microinjection of glutamate, bicuculline, naratriptan, pituitary adenylate cyclase-activating polypeptide-38 and quinpirole were measured, and blood glucose levels assessed pre- and post-microinjection.Results: Glutamatergic stimulation of ventral tegmental area parabrachial pigmented nucleus neurons reduced nociceptive and spontaneous trigeminocervical complex neuronal firing. Naratriptan, pituitary adenylate cyclase-activating polypeptide-38 and quinpirole inhibited trigeminovascular spontaneous activity, and trigeminocervical complex neuronal responses to dural-evoked electrical and mechanical noxious stimulation. Trigeminovascular sensory processing through modulation of the ventral tegmental area parabrachial pigmented nucleus resulted in reduced circulating glucose levels.Conclusion: Pharmacological modulation of ventral tegmental area parabrachial pigmented nucleus neurons elicits changes in trigeminovascular sensory processing. The interplay between ventral tegmental area parabrachial pigmented nucleus activity and the sensory processing by the trigeminovascular system may be relevant to understand associated sensory and homeostatic symptoms in susceptible migraine patients.